Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Jason Daly Sells 210,000 Shares

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Jason Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total value of $3,654,000.00. Following the completion of the sale, the executive vice president directly owned 35,171 shares in the company, valued at $611,975.40. This represents a 85.65% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $17.27 on Friday. The stock has a market capitalization of $5.51 billion, a price-to-earnings ratio of 35.24 and a beta of 1.27. The business’s 50 day moving average is $17.15 and its two-hundred day moving average is $14.56. Amneal Pharmaceuticals, Inc. has a 12-month low of $9.15 and a 12-month high of $19.26. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMRX. Intech Investment Management LLC grew its position in shares of Amneal Pharmaceuticals by 1.2% in the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock valued at $1,229,000 after purchasing an additional 1,159 shares during the last quarter. Hsbc Holdings PLC increased its stake in shares of Amneal Pharmaceuticals by 1.6% during the 4th quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after purchasing an additional 1,569 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Amneal Pharmaceuticals by 2.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after purchasing an additional 1,582 shares during the last quarter. Comerica Bank raised its position in shares of Amneal Pharmaceuticals by 56.1% during the 4th quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after purchasing an additional 1,685 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in Amneal Pharmaceuticals in the 4th quarter valued at approximately $26,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Key Stories Impacting Amneal Pharmaceuticals

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Amneal entered the second half of 2026 with higher guidance and a broader product pipeline, supporting the company’s growth outlook. However, erosion of its Rytary product remains a concern. Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
• Positive Sentiment: The Kashiv transaction gives Amneal an integrated biosimilars platform that could become a significant long-term growth engine, expanding its pipeline and commercial opportunities. Integration, regulatory execution and product adoption are key hurdles. Can Amneal’s Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
• Neutral Sentiment: Brokerages have a consensus price target of $17.67, indicating limited potential upside relative to recent trading levels and suggesting analysts see a fairly balanced risk-reward profile. Amneal Pharmaceuticals Receives $17.67 Consensus Price Target
• Neutral Sentiment: AMRX has rallied 44.8% over three months, but the advance now faces tests from upcoming earnings, new product launches and pipeline progress. Its higher valuation and Rytary revenue erosion could limit further gains. AMRX Stock Surges 44.8% in 3 Months
• Negative Sentiment: Amneal executives disclosed sizable stock sales. EVP Jason B. Daly sold 210,000 shares for approximately $3.65 million and an additional 6,613 shares, while EVP Nikita Shah sold 146,403 shares for approximately $2.56 million. The transactions substantially reduced their ownership stakes and may be weighing on investor sentiment, although insider sales do not necessarily indicate deteriorating fundamentals. Amneal Executive Stock Sale Filings

Analysts Set New Price Targets

AMRX has been the subject of a number of recent analyst reports. The Goldman Sachs Group reissued a “buy” rating and issued a $21.00 target price on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. Zacks Research raised shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. UBS Group increased their price target on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Barclays raised their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Finally, Weiss Ratings downgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $17.67.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.